| Name | Title | Contact Details |
|---|
VentiRx Pharmaceuticals Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Entegrion is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Diagenode is a leading global provider of complete solutions for epigenetics research, biological sample preparation, and diagnostics assays based in Liege, Belgium and NJ, USA. The company has developed a comprehensive approach to gain new insights into epigenetics studies. The company offers innovative Bioruptor® shearing and IP-Star® automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company`s latest innovations include a unique, full automation system, the industry`s most validated antibodies, the Megaruptor shearing system for long fragment generation in sequencing, and epigenetics assay services.
AnaptysBio is a privately-held antibody development company focused on novel programs in immuno-oncology and inflammation. The Company`s first-in-class proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and peanut allergy, and ANB019, an anti-IL-36 receptor antibody for the treatment of generalized pustular psoriasis. AnaptysBio`s SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery and optimization, which replicates key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Novartis, Gilead, Celgene, Momenta and TESARO.
Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.